Search clinical trials for: partial onset seizures

Total 4574 results

SK Life Science, Inc.

Not yet recruiting

Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy

Focal Onset Seizure
Rapport Therapeutics Inc.

Not yet recruiting

Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy

Focal Onset Seizures
Esraa Mostafa Ahmed Abdel Aal

Not yet recruiting

Inflammatory Biomarkers in Psychogenic Non-epileptic Seizure (seizure)

Localization-Related (Focal) (Partial) Idiopathic Epilepsy and Epileptic Syndromes With Seizures of Localized Onset | TRAIL: Tumor Necrosis Factor Related Apoptosis Inducing Ligand MCP-2 | MCP-2: Monocyte Chemo-attractant Protein-2
SK Life Science, Inc.

Recruiting

Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

Partial Epilepsy

United States, Spain, Korea, Republic of, Germany, Australia, Poland, Hungary
SK Life Science, Inc.

Recruiting

Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures

Partial Epilepsy

Korea, Republic of, United States
NeuroPace

Recruiting

RNS System RESPONSE Study (RESPONSE)

Epilepsy | Drug Resistant Epilepsy | Focal Epilepsy | Partial Seizure | Neurostimulator; Complications

United States
Eisai Inc.

Recruiting

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

Partial-onset Seizures | Pediatric Epileptic Syndrome

United States, Spain, France, Belgium, Czechia, Denmark, Germany
University of North Carolina, Chapel Hill
Focused Ultrasound Foundation

Recruiting

A Pilot Study: Focused Ultrasound Thalamotomy for the Prevention of Secondary Generalization in Focal Onset Epilepsy

Partial Seizures With Secondary Generalization

United States
Cerevel Therapeutics, LLC

Active, not recruiting

An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

Seizures

United States, Spain, Australia, Poland, Ukraine, Serbia
Cerevel Therapeutics, LLC

Active, not recruiting

A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

Seizures

United States, Spain, Australia, Serbia, Poland, Ukraine
SK Life Science, Inc.

Completed

Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

Partial Epilepsy

United States, Spain, Korea, Republic of, Serbia, Germany, Bulgaria, Argentina, Australia, Chile, Czechia, Hungary, Mexico, Poland, Russian Federation, Sweden, Thailand, Ukraine
Neurocrine Biosciences

Terminated

Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures

Focal Onset Seizure | Focal Onset Epilepsy

Spain, Australia, Belgium, Czechia, France, Hungary, Italy
UCB S.A. - Pharma Sector

Completed

Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures

Epilepsy, Partial

United States
UCB Pharma SA

Completed

Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy

Epilepsy

United States, Belgium, Czechia, France, Germany, Hungary, Ireland, Italy, Mexico, Poland, Spain, United Kingdom
İpek Dokurel

Active, not recruiting

Does Levetiracetam and Carbamazepine Impact the Autonomic Activity of Children With Self-limiting Focal Epilepsy? (levcbz)

Epilepsy; Syndrome, Seizures of Localized Onset

Turkey
Neurocrine Biosciences

Completed

A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures

Focal Onset Seizure | Focal Onset Epilepsy

Spain, Belgium, Czechia, France, Italy, Australia, Hungary, United Kingdom
UCB Pharma SA

Completed

Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam

Epilepsy, Partial

Canada, United States
Marinus Pharmaceuticals

Terminated

A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures

Drug Resistant Partial Onset Seizure

United States
Eisai Inc.

Completed

A Post-marketing Observational Study Of The Use Of Zonisamide (ZNS) in the Adjunctive Treatment Of Adult Patients With Partial Onset Seizures (Study E2090-E044-410) (ZOOM)

Partial Onset Seizures

Germany, Sweden, Norway, Austria, Denmark
UCB Biopharma S.P.R.L.
Parexel

Completed

A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994

Epilepsy

Bulgaria, Finland, France, Germany, Japan, Korea, Republic of, Latvia, Mexico, Philippines, Poland, Romania, Russian Federation, Sweden, Switzerland, Ukraine
Eisai Inc.

Available

An Extended Access Program (EAP) for Perampanel

Lennox Gastaut Syndrome | Primary Generalized Tonic-Clonic or Partial Onset Seizures

Belgium, Chile, Estonia, Hungary, Latvia, Lithuania, Poland, Spain
Marinus Pharmaceuticals

Completed

A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures

Partial Epilepsy | Catamenial Epilepsy

United States
Marinus Pharmaceuticals

Completed

Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension

Drug Resistant Partial Onset Seizure

United States, Australia, Russian Federation, Bulgaria, Germany, Poland
Eisai Limited

Completed

A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy

Idiopathic Generalized Epilepsy | Partial Onset Seizures | Generalised Tonic-Clonic Seizures

France, Spain, Italy, Denmark, Germany, Portugal, Russian Federation
Marinus Pharmaceuticals

Completed

Open-label Extension to Protocol 1042-0600

Epilepsies, Partial

United States
Eisai Inc.

Completed

Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures

Partial-Onset or Primary Generalized Tonic-Clonic Seizures

Canada, France, Italy, Korea, Republic of, Spain, United States, Belgium, Czechia, Hungary, Japan, Latvia, Poland
UCB BIOSCIENCES, Inc.
UCB Biopharma SRL

Completed

A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures

Epilepsy

United States, Argentina, Australia, Belgium, Brazil, Bulgaria, China, Colombia, Croatia, Czechia, Estonia, France, Georgia, Greece, Hungary, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Mexico, Moldova, Republic of, Monten... and more
Eisai Co., Ltd.

Completed

Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures (FYC02T)

Partial Seizures (With or Without Secondary Generalized Seizures) | Primary Generalized Tonic-clonic Seizures

Japan
UCB Pharma

Completed

Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures (BRITE)

Epilepsy

United States, Czechia, Germany, Poland, Austria, Belgium, Brazil, Bulgaria, Canada, Estonia, Finland, France, Hong Kong, Hungary, India, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Netherlands, Puerto Rico, Russian Federation and more
UCB Pharma

Completed

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

Epilepsy

United States, Australia, Canada, Brazil, Mexico
UCB Pharma SA

Completed

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

Epilepsy

Belgium, Finland, France, Germany, Hungary, India, Italy, Netherlands, Poland, Spain, Switzerland, United Kingdom
Eisai Inc.

Completed

Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

Partial Onset Seizures | Primary Generalized Tonic-Clonic Seizures | Secondarily Generalized Seizures

United States
SK Life Science, Inc.

Completed

A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

Partial Epilepsy

Australia, United States, Korea, Republic of, Germany, Hungary, Serbia, Bulgaria, Czechia, France, Israel, Poland, Romania, Spain, Thailand, Ukraine
SK Life Science, Inc.

Completed

Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures

Partial Epilepsy

Korea, Republic of, United States, India, Poland
UCB Biopharma SRL

Terminated

An Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy

Highly Drug-resistant Focal Epilepsy

Belgium, Bulgaria, Germany, Hungary, Netherlands, Spain
Eisai Co., Ltd.

Completed

Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adult Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures (FYC01S)

Partial Seizures (With or Without Secondary Generalized Seizures) | Primary Generalized Tonic-clonic Seizures

Japan
SK Life Science, Inc.

Approved for marketing

Cenobamate Expanded Access Program (EAP)

Partial Epilepsy
UCB Pharma SA
UCB Japan Co. Ltd.

Completed

Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures

Epilepsy | Partial-onset Seizures

China, Japan
UCB BIOSCIENCES, Inc.

Completed

Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy (BRITE™)

Epilepsy

Czechia, Germany, Poland, Austria, Belgium, Brazil, Canada, Estonia, Finland, France, Hong Kong, Hungary, India, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Netherlands, Puerto Rico, Russian Federation, Spain, Sweden, T... and more
UCB PHARMA Inc. (US)

Completed

This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment

Epilepsy

United States, Australia, Brazil, Canada, India, Mexico
Eisai Korea Inc.

Completed

A Study of Fycompa (Perampanel) in Korean Participants

Epilepsy

Korea, Republic of
Eisai Co., Ltd.

Completed

Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Participants With Partial Onset Seizures (Including Secondarily Generalized Seizures (FREEDOM Study)

Partial Onset Seizures

Japan, Korea, Republic of
UCB Biopharma S.P.R.L.
Pharm Research Associates (UK) Ltd.

Completed

Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures (BASE)

Epilepsy With POS With or Without Secondary Generalization

Denmark, Germany, Hungary, Ireland, Italy, Netherlands, Norway, Spain, United Kingdom
Eisai Co., Ltd.

Completed

A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures

Partial-onset Seizures

Korea, Republic of, Japan, Australia, China, Malaysia, Taiwan, Thailand
UCB BIOSCIENCES, Inc.

Completed

Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures

Epilepsy With Partial-onset Seizures

United States, Argentina, Brazil, Bulgaria, China, Croatia, Czechia, France, Georgia, Greece, Hungary, Israel, Italy, Korea, Republic of, Mexico, Moldova, Republic of, Philippines, Poland, Portugal, Romania, Russian Federation, Se... and more
Novartis Pharmaceuticals

Completed

Phase II BGG492 Capsule Extension for Partial Epilepsy

Partial Onset Seizures

Germany, United States, Hungary, Korea, Republic of, Poland, Slovakia
Eisai Pharmaceuticals India Pvt. Ltd

Completed

A Study to Assess Safety and Efficacy of Perampanel in Indian Participants as an Adjunctive Treatment in Partial Onset Seizures With or Without Secondary Generalized Seizures in Participants With Epilepsy Aged 12 Years or Older

Epilepsy | Partial Onset Seizures

India
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures

Epilepsies, Partial

United States, Korea, Republic of, Mexico
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures

Epilepsies, Partial

United States, Mexico, Korea, Republic of
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures

Epilepsy, Partial Seizures | Epilepsy, Primary Generalized Tonic-Clonic Seizures

United States, Korea, Republic of, Taiwan, Lebanon, Singapore, Malaysia, China, Spain, Bulgaria, Czechia, United Kingdom, Israel, Russian Federation, France, Belarus, Belgium, Bosnia and Herzegovina, Germany, Greece, Hungary, India and more

Search clinical trials for: partial onset seizures

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations